	US 11,999,805 B1
	Peptide inhibitors of CRISPR-Cas9
Brooke Nicole Harmon, Livermore, CA (US); Yooli Kim Light, Pleasanton, CA (US); Mary Bao Tran-Gyamfi, Pleasanton, CA (US); Joseph S. Schoeniger, Oakland, CA (US); Edwin A. Saada, Dublin, CA (US); and Kenneth L. Sale, Pleasanton, CA (US)
Assigned to National Technology & Engineering Solutions of Sandia, LLC, Albuquerque, NM (US)
Filed by National Technology & Engineering Solutions of Sandia, LLC, Albuquerque, NM (US)
Filed on May 6, 2020, as Appl. No. 16/867,698.
Int. Cl. C07K 7/08 (2006.01); A61K 38/46 (2006.01); C07K 14/00 (2006.01); A61K 9/00 (2006.01)

CPC C07K 7/08 (2013.01) [A61K 38/465 (2013.01); C07K 14/001 (2013.01); A61K 9/0053 (2013.01); C12N 2310/20 (2017.05); C12N 2310/3513 (2013.01); C12N 2310/3519 (2013.01); C12Y 301/00 (2013.01)]

18 Claims

1. An agent selected from the group consisting of: an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1, 3-10, and 12-28 and combinations thereof;

wherein the sequence identity is calculated over a full length of the amino acid sequence.